IDEXX Laboratories Inc
IDXX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000874716
In the last 90 days, IDEXX Laboratories Inc insiders filed 0 open-market purchases and 1 sale; 1,306 institutions reported holding it in 13F filings for Q2 2026, worth $39.1B in total; 3 superinvestors hold it, including Fundsmith and Weitz Investment Management.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by IDEXX Laboratories Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $1.17M in total
- Insiders trading
- 1
- Net value
- −$1.17M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for IDEXX Laboratories Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kingsley Lawrence D | Director | 9,568 | Sep 9, 2026 | 3 |
| Emerson Andrew | EVP, CFO and Treasurer | 4,421 | Aug 24, 2026 | 2 |
| Hooley Joseph L | Director | 325 | Aug 3, 2026 | 6 |
| Fennell George | Executive Vice President | 10,433 | Jun 2, 2026 | 3 |
| Junius Daniel M | Director | 3,561 | May 14, 2026 | 2 |
| Essig Stuart | Director | 2,236 | May 14, 2026 | 1 |
| Claflin Bruce L. | Director | 161 | May 14, 2026 | 1 |
| Vandebroek Sophie V. | Director | 905 | May 14, 2026 | 3 |
| Britt Irene Chang | Director | 208 | May 14, 2026 | 1 |
| Samad Sam | Director | – | May 14, 2026 | 1 |
| Peacock Karen | Director | 102 | May 14, 2026 | 3 |
| Szostak M Anne | Director | 519 | May 11, 2026 | 1 |
| Underberg Sharon E. | EVP, GC & Corporate Secretary | 7,138 | Mar 5, 2026 | 2 |
| Hunt Nimrata | Executive Vice President | 18,141 | Mar 5, 2026 | 4 |
| Erickson Michael G | Executive Vice President | 12,693 | Mar 3, 2026 | 2 |
| Mazelsky Jonathan Jay | President and CEO | 83,803 | Mar 2, 2026 | 2 |
| Smith Martin Alexander | Executive Vice President | 2,157 | Feb 17, 2026 | 1 |
| Lane Michael | Executive Vice President | 8,024 | Feb 17, 2026 | 1 |
| Johnson Michael Perkins | Executive Vice President | 2,795 | Feb 17, 2026 | 1 |
| Schreck Michael | Executive Vice President | 3,089 | Feb 17, 2026 | 1 |
| McKeon Brian P | EVP, CFO and Treasurer | 31,550 | Feb 18, 2025 | 0 |
| Ayers Jonathan W | Director | 122,605Indirect | Sep 9, 2024 | 0 |
| COLLINS Asha | Director | 779 | May 8, 2024 | 0 |
| Polewaczyk James F | Executive Vice President | 10,711 | Mar 7, 2024 | 0 |
| Turner Kathy V | Senior Vice President | 7,380 | Feb 17, 2023 | 0 |
| Twigge Giovani | Senior Vice President | 20,329 | Feb 25, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 1, 2021 (view filing) | Nov 29 | 2 days | Polewaczyk James FExecutive Vice President | SSale | −4.59K | $633.00 | −$2.91M | −23.7%14.8K after | |
| Nov 15, 2021 (view filing) | Nov 12 | 3 days | McKeon Brian PExecutive VP & CFO | SSale | −9.22K | $620.72 | −$5.73M | −26.0%26.3K after | 2 lots |
| Nov 12, 2021 (view filing) | Nov 10 | 2 days | McKeon Brian PExecutive VP & CFO | SSale | −20.0K | $624.96 | −$12.5M | −43.2%26.3K after | 9 lots |
| Nov 10, 2021 (view filing) | Nov 8-9 | 2 days | McKeon Brian PExecutive VP & CFO | SSale | −16.3K | $629.05 | −$10.3M | −38.3%26.3K after | 10 lots |
| Aug 31, 2021 (view filing) | Aug 27-30 | 4 days | Turner Kathy VSenior Vice President | SSale | −2.53K | $686.21 | −$1.73M | −46.8%2.88K after | 3 lots |
| Aug 31, 2021 (view filing) | May 28 | 95 days | Turner Kathy VSenior Vice President | SSale | −2.00K | $558.44 | −$1.12M | −41.1%2.87K after | Amended |
| Aug 17, 2021 (view filing) | Aug 13-16 | 4 days | Mazelsky Jonathan JayPresident & CEO | SSale | −6.00K | $675.21 | −$4.05M | −10.8%49.4K after | 7 lots |
| Aug 12, 2021 (view filing) | Aug 10 | 2 days | Junius Daniel MDirector | SSale | −2.40K | $679.58 | −$1.63M | −45.3%2.90K after | |
| Aug 9, 2021 (view filing) | Aug 6 | 3 days | Szostak M AnneDirector | SSale | −3.00K | $687.87 | −$2.06M | −29.4%7.22K after | 10 lots |
| Aug 9, 2021 (view filing) | Aug 5 | 4 days | Hunt NimrataExecutive Vice President | SSale | −538 | $703.00 | −$378.2K | −6.2%8.11K after | |
| Aug 5, 2021 (view filing) | Aug 3-4 | 2 days | Twigge GiovaniSenior Vice President | SSale | −20.3K | $698.25 | −$14.2M | −54.2%17.1K after | 5 lots |
| Aug 5, 2021 (view filing) | Aug 3 | 2 days | Lane MichaelExecutive Vice President | SSale | −7.00K | $691.62 | −$4.84M | −65.7%3.65K after | 18 lots |